Grant Award Details

Chimeric Antigen Receptor Targeting Spike Glycoprotein of SARS-cov2
Grant Number: 
DISC2COVID19-12016
Project Objective: 
  • To develop an allogeneic, iPSC-derived CAR NK cell therapy targeting SARS-CoV-2
Investigator: 
Type: 
PI
Disease Focus: 
COVID-19
Infectious Disease
Respiratory Disorders
Human Stem Cell Use: 
iPS Cell
Award Value: 
$249,996
Status: 
Active

Grant Application Details

Application Title: 
  • Chimeric Antigen Receptor Targeting Spike Glycoprotein of SARS-cov2
Public Abstract: 

Research Objective

We expect to generate iPSC derived NK cells expressing a CAR against SARS-cov2 that could be used as an off-the-shelf therapy for COVID-19

Impact

The proposed studies will provide a novel therapeutic approach to boost the cellular immunity against SARS-cov2, especially for high risk populations.

Major Proposed Activities

  • Construction of SARS-cov2 CAR constructs
  • Generation of iPSC-derived NK cells expressing CARs
  • Differentiation of iPSC-CAR cells into hematopoietic progenitors
  • Derivation of human NK-CAR cells
  • In vitro studies of iPSC derived NK-CAR cells
  • In vivo studies of iPSC-derived NK CAR cells
Statement of Benefit to California: 

The SARS-cov2 is the etiological agent of COVID-19, a global pandemic that has caused more than 4200 deaths in California. The proposed studies will provide a novel therapeutics to improve the immune response to COVID-19.